Evoke Pharma (EVOK) News Today $5.21 -0.08 (-1.51%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$5.22 +0.00 (+0.10%) As of 09/5/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVOK Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Contrasting Evoke Pharma (NASDAQ:EVOK) and Supernus Pharmaceuticals (NASDAQ:SUPN)September 6 at 3:49 AM | americanbankingnews.comEvoke Pharma (NASDAQ:EVOK) Stock Rating Upgraded by Wall Street ZenAugust 30, 2025 | americanbankingnews.comEvoke Pharma, EVERSANA expand GIMOTI access with Omnicell relationshipAugust 26, 2025 | msn.comEvoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell RelationshipAugust 26, 2025 | globenewswire.comEvoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange BookAugust 21, 2025 | globenewswire.comEvoke Pharma, Inc. (NASDAQ:EVOK) Just Reported Earnings, And Analysts Cut Their Target PriceAugust 17, 2025 | finance.yahoo.comEvoke Pharma Reports Strong Q2 2025 Sales GrowthAugust 15, 2025 | msn.comEvoke Pharma reports Q2 EPS (62c) vs (93c) last yearAugust 14, 2025 | msn.comEvoke Pharma sees FY25 net product sales of approx $16MAugust 14, 2025 | msn.comEvoke Pharma, Inc.: Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14, 2025 | finanznachrichten.deEvoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14, 2025 | finance.yahoo.comEvoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038August 6, 2025 | globenewswire.comEvoke Pharma Initiates Commercial Manufacturing of Gimoti™August 5, 2025 | cnn.comEvoke Pharma Receives Notice of Allowance for U.S. Patent ... - NasdaqJuly 11, 2025 | nasdaq.comEvoke Pharma, Inc. Receives Patent Allowance for GIMOTI® in ... - NasdaqJuly 11, 2025 | nasdaq.comEvoke Pharma Stock Skyrockets On Patent For Nasal Spray That Eases Stomach Delays; Retail Bulls Pile InJuly 10, 2025 | msn.comEvoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036July 9, 2025 | globenewswire.comBreakeven On The Horizon For Evoke Pharma, Inc. (NASDAQ:EVOK)June 14, 2025 | finance.yahoo.comEvoke Pharma Inc.June 8, 2025 | wsj.comEvoke Pharma Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comEvoke Pharma Announces Presentation of New Research on Tardive Dyskinesia at Digestive Disease Week 2025April 30, 2025 | nasdaq.comEvoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025April 28, 2025 | globenewswire.comEvoke Pharma, Inc. (NASDAQ:EVOK) Just Reported And Analysts Have Been Cutting Their EstimatesMarch 16, 2025 | uk.finance.yahoo.comEarnings call transcript: Evoke Pharma Q4 2024 reports strong sales growthMarch 15, 2025 | uk.investing.comQ4 2024 Evoke Pharma Inc Earnings CallMarch 14, 2025 | finance.yahoo.comEvoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comEvoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ...March 13, 2025 | gurufocus.comEvoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 13, 2025 | globenewswire.comEvoke Pharma, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025March 6, 2025 | quiverquant.comQEvoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025March 6, 2025 | globenewswire.comEvoke Pharma, Inc. Appoints Greg Pyszczymuka to Board of Directors, Strengthening Commercial StrategyFebruary 24, 2025 | quiverquant.comQEvoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of DirectorsFebruary 24, 2025 | globenewswire.comEvoke underscores committment to patients after FDA update on domperidoneDecember 20, 2024 | markets.businessinsider.comEvoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply EndsDecember 19, 2024 | globenewswire.comEvoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®December 3, 2024 | globenewswire.comEvoke Pharma Third Quarter 2024 Earnings: Misses ExpectationsNovember 10, 2024 | finance.yahoo.comEvoke Pharma Reports Q3 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comEvoke Pharma, Inc. Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | globenewswire.comEvoke Pharma Shares Soar on Positive Data for Gimoti Nasal Treatment in Diabetic GastroparesisOctober 29, 2024 | finance.yahoo.comEvoke Pharma trading halted, volatility trading pauseOctober 29, 2024 | markets.businessinsider.comEvoke Pharma Stock Is Soaring Monday: What's Going On?October 28, 2024 | benzinga.comEvoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®October 28, 2024 | finance.yahoo.comEvoke stock rockets 90% on study of Gimoti in GLP-1 usersOctober 28, 2024 | msn.comEvoke Pharma Shares Rise 70% on Gimoti Data in GLP-1 UsersOctober 28, 2024 | marketwatch.comEvoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific MeetingOctober 23, 2024 | globenewswire.comEvoke Pharma appoints Ben Smeal to board of directorsOctober 23, 2024 | markets.businessinsider.comEvoke Pharma Appoints Benjamin Smeal as DirectorOctober 23, 2024 | markets.businessinsider.comEvoke Pharma Announces the Appointment of Ben Smeal to the Board of DirectorsOctober 22, 2024 | globenewswire.com"Clear and very legitimate interest": Blinken offers support for Israel's actions against HezbollahOctober 12, 2024 | msn.comUS announces sanctions targeting Iran's petroleum, petrochemical sectors over Israel attackOctober 12, 2024 | msn.com Get Evoke Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVOK Media Mentions By Week EVOK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EVOK News Sentiment▼0.000.72▲Average Medical News Sentiment EVOK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EVOK Articles This Week▼11▲EVOK Articles Average Week Get the Latest News and Ratings for EVOK and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Evoke Pharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies THAR News DYAI News RNTX News RVPH News ITRM News CLSD News ASBP News CASI News KZR News PMN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EVOK) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
